NICE Backs New Targeted Therapy for Advanced Cervical Cancer Edited by Zeel Mehta Medscape UK May 22, 2026

https://www.medscape.com/viewarticle/nice-backs-new-targeted-therapy-advanced-cervical-cancer-2026a1000gmb The National Institute for Health and Care Excellence (NICE) has recommended tisotumab vedotin (Tivdak, Genmab) as an option for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment in adults.

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer?utm_medium=email&utm_source=govdelivery On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

From pig to patient Pioneering transplants from pigs to humans could mark a turning point for organ replacement. Written byAndrea Corona

https://www.drugdiscoverynews.com/from-pig-to-patient-16896?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9Kdpv8fqN7BJeaJy7zEesF8mMHlKlDo2SQjkDaY8fFZoXk-AAj4cU2Hdil2c3gK4H-9Nvg32AUE8a1L1AjMFku4x8q4w&_hsmi=419757017&utm_content=419757017&utm_source=hs_email Tim Andrews, 67, has now lived more than eight months with a genetically-engineered pig kidney, making him the longest-living human recipient of such an organ to date. Discharged from dialysis and thriving, he stands at the vanguard of a shift in transplantation science. At the same time, biotechnology firm eGenesis has just won FDA clearance to begin a full clinical trial of its porcine kidney candidate EGEN-2784. Together, these developments mark what may be a turning point with xenotransplantation no longer being speculative science, but a nascent therapy entering human trials.

What does it mean when lupus goes quiet? A $15 million international study is investigating patients in long-term remission to understand whether lupus can truly switch off — and what that reveals about the immune system. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/what-does-it-mean-when-lupus-goes-quiet-17178?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9atg6hqdR_lfJ_m-yIvP2YG-gnxKZMXwvYS4b0wjjdmZYlFMBLdtwBm9q1BZ7VOavJczj7PxVYLVNVRNIDdcFv6PoAYA&_hsmi=419757017&utm_content=419757017&utm_source=hs_email When Hazel Harris was diagnosed with systemic lupus erythematosus (SLE) in 1986, she had never heard of the disease. She was 33 years old, busy, energetic, and always on the move. Then her body began to change in ways she couldn’t explain. First came the rash on her face, in the shape of a butterfly. Then her eyes grew puffy. This was followed by a deep fatigue that was extremely unlike her. Finally, her leg began to swell so badly that she could no longer walk. “That’s when I had no choice but to go to the doctor,” she told DDN.

Connect With Your Patient Living With Depression: Are They a Good Candidate for an Augmentation Treatment? Authors: Marlene Freeman, MD

https://www.medscape.org/viewarticle/connect-your-patient-living-depression-are-they-good-2026a1000fox?page=1&src=wnl_tpal_260521_mscpedu&uac=148436CN&impID=8361821

Charting New Frontiers in Advanced Breast Cancer: Milestones, Missions, and Mastery Authors: Paolo Tarantino, MD, PhD; Kevin Kalinsky, MD, MS, FASCO; Sibylle Loibl, MD, PhD

https://www.medscape.org/viewarticle/charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7?page=1&src=wnl_tpal_260521_mscpedu&uac=148436CN&impID=8361821

Highlights From the Annual Neuro-Oncology Conference: Integrating IDH Inhibitor Therapy Into Glioma Care Authors: Maciej Mrugala, MD, PhD, MPH; Rimas V. Lukas, MD; Yoshie Umemura, MD

https://www.medscape.org/viewarticle/1003175?src=mkmcmr_driv_stan_mscpedu_260521-OUS-HONC-1003175-cta&uac=148436CN